Flt3L therapy increases the abundance of Treg-promoting CCR7
Flt3L
breast cancer
combination therapies
dendritic cell
immunotherapy
lung cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
02
2023
accepted:
25
07
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Conventional dendritic cells (cDCs) are at the forefront of activating the immune system to mount an anti-tumor immune response. Flt3L is a cytokine required for DC development that can increase DC abundance in the tumor when administered therapeutically. However, the impact of Flt3L on the phenotype of distinct cDC subsets in the tumor microenvironment is still largely undetermined. Here, using multi-omic single-cell analysis, we show that Flt3L therapy increases all cDC subsets in orthotopic E0771 and TS/A breast cancer and LLC lung cancer models, but this did not result in a reduction of tumor growth in any of the models. Interestingly, a CD81
Identifiants
pubmed: 37622122
doi: 10.3389/fimmu.2023.1166180
pmc: PMC10445485
doi:
Substances chimiques
Receptors, CCR7
0
CD40 Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1166180Informations de copyright
Copyright © 2023 Clappaert, Kancheva, Brughmans, Debraekeleer, Bardet, Elkrim, Lacroix, Živalj, Hamouda, Van Ginderachter, Deschoemaeker and Laoui.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2016 Dec 23;7:13720
pubmed: 28008905
Blood. 1996 Sep 15;88(6):2004-12
pubmed: 8822919
Front Immunol. 2021 Oct 19;12:749190
pubmed: 34737750
J Exp Med. 2019 May 6;216(5):1170-1181
pubmed: 30910796
Cancer Res. 2022 Oct 17;82(20):3785-3801
pubmed: 35979635
J Exp Med. 2003 Jul 21;198(2):305-13
pubmed: 12874263
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Immunol Rev. 2010 Mar;234(1):45-54
pubmed: 20193011
Immunol Cell Biol. 2021 Oct;99(9):962-971
pubmed: 34097779
J Immunol. 2002 Dec 15;169(12):6691-5
pubmed: 12471100
Front Immunol. 2012 Jul 03;3:183
pubmed: 22783257
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091774
Nature. 2020 Apr;580(7802):257-262
pubmed: 32269339
Bioengineered. 2021 Dec;12(1):6923-6934
pubmed: 34569432
Nat Immunol. 2008 Jun;9(6):676-83
pubmed: 18469816
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Front Oncol. 2021 Apr 16;11:562315
pubmed: 33937012
J Immunol. 2016 Mar 15;196(6):2561-71
pubmed: 26851220
Sci Rep. 2020 Apr 24;10(1):6969
pubmed: 32332834
Cancer Res. 2015 Nov 1;75(21):4517-26
pubmed: 26329536
Nat Cancer. 2020 Dec;1(12):1204-1217
pubmed: 35121932
Adv Exp Med Biol. 2020;1231:23-32
pubmed: 32060843
Blood. 2009 Jun 18;113(25):6277-87
pubmed: 19211508
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810248
Blood. 2011 Aug 18;118(7):1818-27
pubmed: 21677313
J Clin Invest. 2004 Mar;113(5):774-83
pubmed: 14991076
Nat Biotechnol. 2020 May;38(5):629-637
pubmed: 32152598
Nat Protoc. 2022 Oct;17(10):2354-2388
pubmed: 35931780
Front Immunol. 2022 Jul 05;13:901277
pubmed: 35865534
Cancer Res. 1998 Feb 1;58(3):380-3
pubmed: 9458075
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601412
Gut. 2012 Aug;61(8):1154-62
pubmed: 22068168
Cancer Gene Ther. 2007 Apr;14(4):364-71
pubmed: 17235356
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630699
Immunity. 2021 Oct 12;54(10):2338-2353.e6
pubmed: 34534439
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nat Neurosci. 2021 Apr;24(4):595-610
pubmed: 33782623
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321